NCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
Second Affiliated Hospital, School of Medicine, Zhejiang University
Jiangsu Cancer Institute & Hospital
Innovent Biologics (Suzhou) Co. Ltd.